Effects of Ergocalciferol on Erythropoetin Stimulating Agent Dose
Status:
Terminated
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
Hypothesis: The supplementation of Ergocalciferol (Vitamin D2) to those with Vitamin D
deficiency in the Chronic Kidney Disease population requiring recombinant human
erythropoietin for the treatment of anemia related to kidney disease will reduce the dose of
erythropoietin required to maintain a nonanemic state.